PU.1/Spi-1 binds to the human TAL-1 silencer to mediate its activity. 2006

Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
Institut de Génétique Moléculaire-UMR5535-IFR22, CNRS 1919 Route de Mende F-34980 Montpellier, France.

The TAL-1/SCL gene encodes a basic helix-loop-helix (bHLH) transcription factor essential for primitive hematopoiesis and for adult erythroid and megakaryocytic development. Activated transcription of TAL-1 as a consequence of chromosomal rearrangements is associated with a high proportion of human T cell acute leukemias, showing that appropriate control of TAL-1 is crucial for the formation and subsequent fate of hematopoietic cells. Hence, the knowledge of the mechanisms, which govern the pattern of TAL-1 expression in hematopoiesis, is of great interest. We previously described a silencer in the 3'-untranslated region of human TAL-1, the activity of which is mediated through binding of a tissue-specific 40 kDa nuclear protein to a new DNA recognition motif, named tal-RE. Here, we show that tal-RE-binding activity, high in immature human hematopoietic progenitors is down regulated upon erythroid and megakaryocytic differentiation. This expression profile helped us to identify that PU.1/Spi-1 binds to the tal-RE sequences in vitro and occupies the TAL-1 silencer in vivo. By expressing a mutant protein containing only the ETS domain of PU.1 in human erythroleukemic HEL cells, we demonstrated that PU.1 mediates the transcriptional repression activity of the silencer. We found that ectopic PU.1 is not able to induce silencing activity in PU.1-negative Jurkat T cells, indicating that PU.1 activity, although necessary, is not sufficient to confer transcriptional repression activity to the TAL-1 silencer. Finally, we showed that the silencer is also active in TAL-1-negative myeloid HL60 cells that express PU.1 at high levels. In summary, our study shows that PU.1, in addition to its positive role in TAL-1 expression in early hematopoietic progenitors, may also act as a mediator of TAL-1 silencing in some hematopoietic lineages.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D015533 Transcriptional Activation Processes that stimulate the GENETIC TRANSCRIPTION of a gene or set of genes. Gene Activation,Genetic Induction,Transactivation,Induction, Genetic,Trans-Activation, Genetic,Transcription Activation,Activation, Gene,Activation, Transcription,Activation, Transcriptional,Genetic Trans-Activation,Trans Activation, Genetic
D015534 Trans-Activators Diffusible gene products that act on homologous or heterologous molecules of viral or cellular DNA to regulate the expression of proteins. Nuclear Trans-Acting Factor,Trans-Acting Factors,Trans-Acting Factor,Trans-Activator,Transactivator,Transactivators,Factor, Nuclear Trans-Acting,Factor, Trans-Acting,Factors, Trans-Acting,Nuclear Trans Acting Factor,Trans Acting Factor,Trans Acting Factors,Trans Activator,Trans Activators,Trans-Acting Factor, Nuclear
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
October 1995, Oncogene,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
May 1996, The Journal of biological chemistry,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
October 1992, Molecular and cellular biology,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
December 1994, Biochimica et biophysica acta,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
May 1996, Molecular and cellular biology,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
May 1995, Blood,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
November 1997, Biochemical and biophysical research communications,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
March 1998, Journal of immunology (Baltimore, Md. : 1950),
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
July 1995, Oncogene,
Mikaël Le Clech, and Elias Chalhoub, and Christiane Dohet, and Virginie Roure, and Serge Fichelson, and Françoise Moreau-Gachelin, and Danièle Mathieu
June 1990, Cell,
Copied contents to your clipboard!